AstraZeneca Launches Phase 3 Trials for Oral GLP-1 Pill That Cut Weight by 12%
Elecoglipron, a once-daily oral GLP-1 receptor agonist, enters Phase 3 trials after showing 11.8% weight loss and meaningful blood sugar reduction.
Summary
AstraZeneca has launched a large global Phase 3 program for elecoglipron, an oral pill that targets the GLP-1 receptor — the same pathway as injectable weight-loss drugs like semaglutide. The Phase 2b trials showed nearly 12% weight loss at 36 weeks and a meaningful drop in HbA1c, a key blood sugar marker. The new Phase 3 program spans obesity, type 2 diabetes, heart failure, and chronic kidney disease. A pill format could make GLP-1 therapy far more accessible than current injections. For longevity-focused adults, GLP-1 drugs are increasingly recognized as tools for reducing cardiometabolic risk — one of the leading drivers of age-related disease and premature death.
Detailed Summary
Elecoglipron, an investigational once-daily oral small-molecule GLP-1 receptor agonist developed by Eccogene and licensed to AstraZeneca, has entered global Phase 3 clinical trials. The milestone triggered a $50 million payment to Eccogene, bringing total earnings under the partnership to $295 million. This marks a significant step forward in the race to develop a convenient pill-based alternative to injectable GLP-1 therapies.
The Phase 3 program is broad and ambitious. The Embold trials will enroll people with obesity or overweight, with and without type 2 diabetes. The Eluminate trials will test elecoglipron as a standalone therapy and in combination with dapagliflozin — an SGLT2 inhibitor with its own proven cardiometabolic benefits — specifically for type 2 diabetes. Two Elevate outcome trials will evaluate whether elecoglipron can improve outcomes in heart failure with mildly reduced or preserved ejection fraction and in chronic kidney disease, both conditions heavily associated with aging and metabolic dysfunction.
Phase 2b data provided solid grounds for this expansion. The VISTA trial demonstrated 11.8% weight loss at 36 weeks, while the SOLSTICE trial showed a 1.9% reduction in HbA1c at 26 weeks. These figures are competitive with early injectable GLP-1 results and suggest meaningful cardiometabolic impact.
For longevity-conscious readers, the significance extends well beyond weight loss. GLP-1 receptor agonists are increasingly recognized as broad cardiometabolic agents that reduce cardiovascular events, improve insulin sensitivity, lower inflammation, and may have neuroprotective properties. An effective oral formulation could dramatically expand access and adherence.
Caveats remain. Phase 3 results will be the true test of safety and efficacy at scale. Long-term durability of weight loss and cardiometabolic benefits, as well as gastrointestinal tolerability, will need close scrutiny before clinical adoption becomes widespread.
Key Findings
- Elecoglipron achieved 11.8% weight loss at 36 weeks in Phase 2b, comparable to early injectable GLP-1 benchmarks.
- HbA1c dropped by 1.9% at 26 weeks, indicating clinically meaningful blood sugar improvement in type 2 diabetes.
- Phase 3 trials now cover obesity, type 2 diabetes, heart failure, and chronic kidney disease — all major age-related conditions.
- An oral once-daily pill format could significantly improve GLP-1 therapy accessibility and long-term adherence.
- Combination trials with dapagliflozin may reveal additive cardiometabolic benefits beyond either drug alone.
Methodology
This is a news report covering a clinical and business milestone rather than a peer-reviewed study. The Phase 2b efficacy data (VISTA and SOLSTICE trials) are described as positive topline results; full data have not yet been peer-reviewed or published in detail. The source, Longevity.Technology, is a credible longevity-focused industry outlet.
Study Limitations
Phase 2b results are topline only and await full publication and peer review. Phase 3 outcomes for heart failure and kidney disease remain speculative. Long-term safety, weight-loss durability, and gastrointestinal tolerability have not yet been established at scale.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: